ACTU insider buying and SEC filings, explained
Actuate Therapeutics, Inc. · CIK 1652935
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$1.6M
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 28, 2026 | Other purchase | Daniel M. Schmitt (CEO and Director) bought 211,266 Common Stock in 2 share classes at about $0.2367 ($50K) in a public offering. Holdings of Common Stock up 47% to 442,560 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 29, 2026, 9:35 AM ET |
| Jan 5, 2026 | Sale | Todd S. Thomson (Director and 10% owner) sold 280,000 shares indirectly (by entity) at $5.80 ($1.6M). Holdings by entity down 24% to 904,795 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 1 other reporting owner. | SEC filing Filed Jan 7, 2026 |
15 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ACTU in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.